e-learning
resources
London 2016
Sunday, 04.09.2016
Possible phenotypes of bronchiectasis and exacerbations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Chronic inhaled corticosteroids in patients with bronchiectasis who suffer an exacerbation
Edmundo Rosales Mayor (Barcelona, Spain), Edmundo Rosales Mayor, Victoria Alcaraz Serrano, Isabel Amara-Elori, Beatriz Montull, Alexandra Gimeno, Gerard Muñoz, Montserrat Vendrell, Rosa María Girón, Rosario Menendez, Polverino Eva, Antoni Torres
Source:
International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Session:
Possible phenotypes of bronchiectasis and exacerbations
Session type:
Poster Discussion
Number:
1548
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Edmundo Rosales Mayor (Barcelona, Spain), Edmundo Rosales Mayor, Victoria Alcaraz Serrano, Isabel Amara-Elori, Beatriz Montull, Alexandra Gimeno, Gerard Muñoz, Montserrat Vendrell, Rosa María Girón, Rosario Menendez, Polverino Eva, Antoni Torres. Chronic inhaled corticosteroids in patients with bronchiectasis who suffer an exacerbation. Eur Respir J 2016; 48: Suppl. 60, 1548
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Exacerbations and inhaled corticosteroids in bronchiectasis patients
Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis
Year: 2019
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
Inhaled corticosteroids and hospitalisation due to exacerbation of COPD
Source: Eur Respir J 2003; 22: 286-289
Year: 2003
Predictors of exacerbations in patients with bronchiectasis
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
The role of nebulised budesonide in the treatment of exacerbations of COPD
Source: Eur Respir J 2007; 29: 660-667
Year: 2007
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Oral corticosteroids in the treatment of exacerbation of severe asthma
Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden
Year: 2020
Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia
Source: Eur Respir J 2011; 37: 36-41
Year: 2011
Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016
Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia
Source: Eur Respir J 2010; 36: 751-757
Year: 2010
Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Risk of pneumonia and exacerbations of chronic obstructive pulmonary disease(COPD) with inhaled corticosteroid (ICS) use: a Singapore perspective
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
Source: Breathe, 16 (3) 200086; 10.1183/20734735.0086-2020
Year: 2020
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
Source: Eur Respir J 2006; 27: 1168-1174
Year: 2006
Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Chronic oral corticosteroids use and persistent eosinophilia in severe asthma. The Belgian Severe Asthma Registry.
Source: Virtual Congress 2020 – Phenotypes of asthma and COPD
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept